تحميل...

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Pharmacotherapy with L-DOPA remains the gold-standard therapy for PD, but is often limited by the development of the common side effect of L-DOPA-induced dyskinesia (LID), which can become debilitating. The only effective...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Exp Neurol
المؤلفون الرئيسيون:	Bartlett, Mitchell J., Flores, Andrew J., Ye, Tony, Smidt, Saskia I., Dollish, Hannah K., Stancati, Jennifer A., Farrell, Drew C., Parent, Kate L., Doyle, Kristian P., Besselsen, David G., Heien, Michael L., Cowen, Stephen L., Steece-Collier, Kathy, Sherman, Scott J., Falk, Torsten
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	2020
الموضوعات:	Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7518549/ https://ncbi.nlm.nih.gov/pubmed/32717354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2020.113413
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

مواد مشابهة